Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection

Recruiting Observational Study
Age-Related (Dry) Macular Degeneration
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 and older
Sex
Any
Study type
Observational
Participants needed
1,000 (estimated)
Sponsor
AI-Spectral · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old. The main questions it aims to answer are: * Does DeepMSI AI detect AMD biomarkers with sensitivity equivalent to experienced clinicians? * Does DeepMSI AI detect AMD biom…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: AMD subjects: 1. Subjects over 40 years of age diagnosed for ne AMD 2. Subject must be able to understand and must sign an IRB-approved ICF 3. Subject must have minimum of one prior visit to the clinic 4. Prior imaging must show signs of neAMD (e.g. drusen of different sizes and…
Contacts

Angela F. Esfandiarinezhad, PhD

16135816702

angela.f@deepmsi.com

CONTACT

Emily Zhang, MD. PhD

EmilyZ@deepmsi.com

CONTACT